Yiyang Xu

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

Eric L. Smith, Kim Harrington, Reed Masakayan et al. · Science Translational Medicine · 2019 · 385 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

Targeting Alpha-Fetoprotein (AFP)–MHC Complex with CAR T-Cell Therapy for Liver Cancer

Hong Liu, Yiyang Xu, Jingyi Xiang et al. · Clinical Cancer Research · 2016 · 230 citations

Life Sciences, Immunology, Oncology +17

Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1

Tao Dao, Dmitry Pankov, Andrew Scott et al. · Nature Biotechnology · 2015 · 161 citations · Full text

Life Sciences, Immunology, Oncology +14

Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector

Eric L. Smith, Reed Masakayan, Ishan J. Tatake et al. · Molecular Therapy · 2018 · 125 citations · Full text

Medicine, Immunology, Oncology +17

A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release

Yiyang Xu, Zhiyuan Yang, Lucas H. Horan et al. · Cell Discovery · 2018 · 121 citations · Full text

Life Sciences, Immunology, Oncology +17